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The incidence of concomitant abdominal aortic aneurysm and gastrointestinal malignancy is rare.
Current treatment strategies in patients with both lesions remain controversial. It is unclear whether to
treat the AAA and gastrointestinal malignancy simultaneously or in a staged manner. In patients with
concomitant AAA and gastrointestinal malignancy surgical orthodoxy dictates that the most symp-
tomatic lesion or the most life threatening condition should be treated ﬁrst, however there is a thera-
peutic dilemma when neither or both of the lesions are symptomatic .In this review we explore (a)
Priority of treatment in patients with concomitant abdominal aortic aneurysm and gastrointestinal
malignancy (b) The role of EVAR in the management of abdominal aortic aneurysm and concomitant
gastrointestinal malignancy.
 2012 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
The management of concomitant abdominal aortic aneurysm
(AAA) and gastrointestinal malignancy is controversial and a ther-
apeutic challenge to the clinician. There is a signiﬁcant paucity of
data in the literature to substantiate the perceived risk/beneﬁt
associated with either a staged approach or a synchronous
approach to the management of concomitant AAA and gastroin-
testinal malignancies. This review attempts to elucidate (a) Priority
of treatment in patients with concomitant abdominal aortic
aneurysm and gastrointestinal malignancy (b) The role of EVAR in
the management of abdominal aortic aneurysm and concomitant
gastrointestinal malignancy.
2. Methods
To identify all relevant studies a computerised search of the English literature
(Medline and embase) from 1990 to till date was performed using the term
(gastrointestinal or colonic or gastric) and (malignancy or neoplasm or cancer or
carcinoma) and (aortic aneurysm). A total of 53 articles were identiﬁed which
included 17 case reports, 34 case series and 2 review articles. Manual searching for
references of these articles were done for additional suitable articles.ad, Romford RM7 0GP, United
das).
Elsevier Ltd on behalf of Surgical3. Incidence
The incidence of concomitant malignancies of all varieties and
AAA ranges between 3 and 13%.1e4 In approximately 9e13% of
patients undergoing pre operative evaluation for AAA treatment,
a concomitant abdominal malignancy will be identiﬁed.3,5e7 The
reported incidence of AAA associated with colorectal cancer varies
from 0.5 to 3.8%.2,34. Aetiology
AAA is deﬁned as a structural failure of the vessel wall resulting
in segmental dilatationwhich increases the normal vessel diameter
by 50% or results in an AP diameter greater than 3 cm.8
AAA formation is most likely a polygenomic disease under the
inﬂuence of environmental factors. Atherosclerosis has been
postulated as an environmental factor.9
The pathophysiology of AAA appears to be due to several factors
including a genetic predisposition caused by mutations in at least
one extra cellular matrix gene and other abnormalities in the
turnover of collagen and elastin. The study by Chan et al. conﬁrms
the possible increased incidence of cancer in patients with AAA
when compared to patients with atherosclerotic occlusive
disease.10Associates Ltd.
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due to collagen lysis induced by the operation itself or may occur
due to weakening of the aneurysmwall from nutritional depletion,
local inﬂammation and surgical dissection.11,12
5. Management of abdominal aortic aneurysm in the presence
of concomitant gastrointestinal malignancy e endovascular
repair versus open repair
Open repair of AAA was ﬁrst introduced in 1952 by Dubost and
colleagues.13 Parodi and colleagues ﬁrst presented the endovas-
cular aortic repair (EVAR) in 1991.14 The advantages with EVAR over
Open repair include (a) Reduced cardiac and respiratory morbidity
(b) Decreased hospital stay and faster recovery (c) Reduced blood
loss and transfusion requirement (d) Can be offered to high risk
patients with severe co morbidities (e) Can be performed under
local or spinal anaesthesia (f) Avoidance of laparotomy (g) Avoid-
ance of aortic clamping and shorter operative time.
However due to the long term durability and high efﬁcacy in
rupture prevention, open repair remains the gold standard in the
treatment of AAA15 despite the documented 30 day mortality for
open repair being 4e12%.16
The UK small aneurysm trial and Lederle et al. have shown that
once the aneurysm attains an appropriate size the risk of rupture
and beneﬁts of repair outweigh the risks of the procedure.17,18
The general consensus is that in a medically ﬁt patient with AAA
large enough to justify intervention, EVAR is preferable for those
with suitable anatomy and with co morbidities likely to limit their
longevity commensurate with the estimated durability of the
device used.19
Generally the decision to treat an AAA depends on the 3 vari-
ables19 (a) AAA size e This factor correlates directly with the risk of
rupture (b) Morphology of the aneurysm e Each endoluminal
device lists strict morphological criteria in its usage instructions. (c)
Patient risks e Depends on whether the patient is ﬁt or a high risk
for open repair. Ruptured or symptomatic AAA (abdominal/back
pain, tenderness over the aneurysm) should undergo surgery
immediately. In case of AAAwhich is more than 5.5 cm in diameter,
the treatment of AAA takes priority in order to avoid the risk of
rupture.
In EVAR 1 Trail, the 30 day mortality of patients who underwent
EVAR was 1.7% compared to 4.7% in patients who underwent open
AAA repair (p e 0.009). After 4 years of follow up, the overall
mortality in the 2 groups was similar, but there was a persistent
reduction in the aneurysm related death in patients who had EVAR
(4% Vs 7%, p e 0.04). On the other hand, there was a higher inci-
dence of complications in patients who had EVAR (41%) when
compared to those who had Open AAA repair (9%) (p < 0.0001).20
In the DREAM trial there was favourable post operative outcome
for EVAR compared to open repair with less operativemortality and
severe systemic complications for patients who are eligible for both
procedures. The advantage was not sustained at 2 year follow up
with similar survival rates in both groups mainly due to increase in
the non aneurysm related mortality in the EVAR group.21
In the OVER trial which used the third and fourth generation
devices, the post operative death was signiﬁcantly lower in the
EVAR group compared to open group. The advantage continued
even after 2 years of follow up.22
In a series by Bush et al., 1904 patients who underwent elective
Open AAA repair or EVAR showed similar results. The patients
undergoing EVAR had signiﬁcant lower 30 day mortality (3.1% vs.
5.6%, p e 0.01). The risk of perioperative complications was
signiﬁcantly reduced after EVAR (15.5% Vs 27.7%).23
In a series of 25 patients who had AAA and concomitant
malignancy by Porcellini et al., patients who underwent EVAR hada lower operative mortality than those who had Open repair. This
advantage was maintained even after a mean follow up of
approximately three years.1
Drury et al. performed a systematic review on the safety and
efﬁcacy of elective EVAR in the management of infra renal AAA. His
ﬁndings illustrated a lower short term morbidity (Cardiac, renal
and pulmonary) and 30 day mortality rate (1.6 versus 4.7%) with
EVAR when compared with open repair.24
The literature to date demonstrates that the short term advan-
tage may be lost on longer follow up because of the late compli-
cations of EVAR.20,21 Howeverwhen applying this knowledge to the
population subgroup who have synchronous malignancy this short
term beneﬁt may be of signiﬁcant value as they in general have
a shorter life expectancy when compared with patients without
malignancy. Furthermore there is a generally accepted consensus
that the long term durability and efﬁcacy of EVARwill improvewith
development in the endovascular devices, reﬁned techniques and
more operator experience.
In patients with concomitant AAA and gastrointestinal malig-
nancy, since EVAR involves a transfemoral approach for placement
of the aortic graft there is no interference with the subsequent
laparotomy and there is no theoretical risk of graft contamination
by the intestinal bacteria.25 As EVAR results in early recovery and
a shorter convalescence period compared with open repair, EVAR
offers potential treatment beneﬁts in patients with suitable
anatomy who have concomitant gastrointestinal malignancy. Thus
it is deduced that in current day practice, EVAR is the preferred
option for treatment of AAA with signiﬁcant co morbidities
including malignancies.
Long term data on durability of EVAR device is lacking .In
comparison with grafts of the ﬁrst generation, the new generation
devices show better long term durability. Since survival in high-risk
patients is low, durability is important if EVAR is used for younger
and healthier patients with AAA. Although the number of compli-
cations following EVAR has decreased signiﬁcantly over the years,
a thorough follow-up is still necessary.26
6. Priority of treatment in concomitant abdominal aortic
aneurysm and gastrointestinal malignancy
6.1. Colorectal cancer and AAA
In patients with concomitant colorectal cancer and AAA, the
most symptomatic lesion or the most life threatening condition
should be treated ﬁrst,3,12,27e29 however there is a therapeutic
dilemma when neither or both of the lesions are symptomatic.
Treatment of the AAA ﬁrst exposes the patients to the risk of
tumour progression whereas treatment of the colorectal cancer
ﬁrst exposes the patient to the risk of AAA rupture in the peri/post
operative period.
Because the majority of the concomitant lesions are asymp-
tomatic at the time of diagnosis, the clinicians are frequently con-
fronted with a therapeutic dilemma. Resection of the colorectal
cancer followed by staged AAA repair may incur potential risks of
aneurysm rupture after cancer operation particularly when the
aneurysm is greater than 5 cm in diameter.3,12,27,29
Combining Colorectal cancer resection with EVAR during
a single procedure is an attractive option in selected patients, but
there is a theoretical risk of graft infection, although not evident in
the small series of patients by Lin et al. and Baxter et al.29,30 In
selective groups of patients, synchronous AAA and Colorectal
cancer treatment has shown favourable results with low risk of
graft infection.29,31e34
In selective patients whose synchronous lesions pose life
threatening symptoms, a single stage approach can be
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mandatory in case of concomitant large/symptomatic AAA and
symptomatic/complicated Colorectal cancer (perforation, obstruc-
tion, haemorrhage), since both lesions are life threatening and
requires urgent treatment.
Ochsner et al. demonstrated that surgery for AAA and nonvas-
cular procedures may be performed simultaneously without
increase in either graft infection or in hospital mortality.37
Conversely other authors report an increased complication rate
after simultaneous treatment38,39 reﬂecting a therapeutic dilemma.
Velanovich and Andersen applied the decision analysis to this
therapeutic dilemma in an attempt to resolve the issue of treat-
ment priority. Their study supported the role of simultaneous
aortic and colorectal surgery if the aneurysm is more than 5 cm in
diameter and the tumour had more than 75% to 80 % chance of
obstruction or perforation provided the combined procedure had
an operative mortality rate of less than 10% and morbidity of less
than 50%.40
In clinical practise when planning treatment, the clinician must
weigh the operative risk of surgical intervention against the disease
related morbidity and mortality of these conditions. These factors
will guide the surgeon whether to repair the AAA or to resect the
colorectal cancer ﬁrst and then do the other procedure in a staged
manner or do both the procedures simultaneously as a synchro-
nous procedure. The availability of EVAR as a treatment option for
AAA has created an alternative paradigm particularly in patients
with synchronous AAA and Colorectal cancer.1Because EVAR
results in early recovery and a shorter convalescence compared
with open repair, EVAR offers potential treatment beneﬁts in
patients with suitable anatomy who have concomitant colorectal
cancer.30
EVAR should be offered with caution because of the risk of
sigmoid ischaemia especially in patients whowill be having colonic
resections. Presumed causes of colonic ischaemia are (a) Inferior
mesenteric artery and/or internal iliac artery occlusion and/or
atheroembolization (b) Non occlusive causes like shock or vaso-
pressive drugs.41e44 Incidence of colonic ischaemia following EVAR
is 1.5e3%.45,46
6.2. Gastric cancer and AAA
In patients with concomitant gastric cancer and AAA, similarly
the symptomatic lesion or the lesion which needs urgent inter-
vention should be treated ﬁrst. In cases of concomitant gastric
cancer and AAA the absolute indication for urgent operation with
regard to AAA is rupture or high possibility of rupture and in case of
gastric cancer is haemorrhage/perforation. In selective patients,
synchronous procedures can be performed safely. If neither of the
lesions warrants urgent surgery, then the decision should be made
on the degree of progression of the cancer.47 If the gastric cancer is
not resectable, AAA repair should not be done except in cases of
rupture or impending rupture.
In a case series by Komori et al., out of 7 patients with
concomitant AAA and gastric cancer, six patients were treated by an
operative intervention. Three patients had the malignancy resected
ﬁrst, one had AAA repair ﬁrst and two patients had synchronous
procedures. Therewas no reported case of post operative aneurysm
rupture among the three patients who underwent cancer resection
ﬁrst. Kamori et al. recommended simultaneous resection using
retroperitoneal approach for AAA repair and transperitoneal
approach for gastric cancer.47
Some of the case series recommend a synchronous operation in
the presence of concomitant gastric and AAA because of the low
risk of graft contamination when compared to colorectal resec-
tions.48e50The lesion that is symptomatic and needs urgent treatment
should be treated ﬁrst. If both the lesions are symptomatic or
advanced then a single staged EVAR followed by gastrectomy can
be performed.33,51,52 If the AAA is not suitable for EVAR then
a single staged Open AAA repair (Retroperitoneal) followed by
gastric cancer resection (Trans peritoneal) can be performed in
selective patients.53
7. Conclusion
Management of concomitant AAA and gastrointestinal malig-
nancy is a therapeutic challenge. In the majority of patients diag-
nosis of concomitant pathology is often incidental during the
imaging study of the primary disease. Decision making is easier for
the clinician if one of the two conditions is life threatening.
When treating patients with AAA and concurrent malignancy,
the surgical approach and timing for the AAA repair remains very
controversial. The decision depends on many variables, including
surgeons experience and preference, local expertise, aneurysm size
and type, stage of the cancer and general condition of the patient.
On the other hand it is mandatory to diagnose and treat gastroin-
testinal malignancy at an earliest stage in order to improve patient
survival. So a considerable delay in the surgery/adjuvant therapy
might have a negative impact on the outcome. Eventually both
lesions should be resected for better long term beneﬁts.
In clinical practice when planning treatment, clinician must
weigh operative risk of surgical intervention against the disease
related mortality of these conditions. In patients with concomitant
gastrointestinal cancer and AAA, the symptomatic lesion should be
a treatment priority.
In patients with concomitant AAA and gastrointestinal malig-
nancy, when both lesions are symptomatic EVAR followed by
resection of the gastrointestinal malignancy as a synchronous or
a staged procedure with a short time period between the two
procedures can be safely done. Hence if the anatomical criteria are
met EVAR could become the optimal solution for patients with
concomitant large AAA and complicated gastrointestinal malig-
nancy who require urgent treatment of both the conditions.
There is no well designed randomised controlled trials with
adequate power, carefully selected inclusion/exclusion criteria,
appropriate measures of outcome and adequate follow up to
address the multiple issues of priority of resection and the need for
synchronous or staged resection in the management of concomi-
tant AAA and gastrointestinal malignancy.
Most published literature consists of small case series and case
reports. In the absence of high level of evidence a multidisciplinary
approach with best available evidence and clinical judgement
should be followed on an individual case basis.
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